Oncology and Hematology News and Journal Articles
The PD-1 inhibitor nivolumab increased progression-free and overall survival compared with chemo in patients with previously untreated metastatic melanoma.
Recent Content
Active surveillance is effective and yields good outcomes in patients with clinical stage I testicular cancer who underwent orchiectomy.
This slide show features pathology slides of astrocytomas, subependymomas, medulloblastomas, meningiomas, ependymomas, glioblastomas, and oligodendrogliomas.
The US Food and Drug Administration has granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small-cell lung cancer.
The FDA has expanded the approved use of ibrutinib (Imbruvica) to include patients with Waldenström macroglobulinemia, a rare type of non-Hodgkin lymphoma.
The benefit of hypofractionated radiotherapy for women receiving breast-conserving therapy for early-stage breast cancer is becoming more apparent.
Using genome-wide association studies, researchers have identified a germline variant that is associated with intolerance to mercaptopurine in pediatric ALL.
Adding molecular breast imaging to mammography resulted in a fourfold increase in invasive breast cancer detection rates in women with dense breasts.
In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.
In this video from the 2014 ASH Annual Meeting, Dr. Röllig discusses the results of the SORAML trial that tested sorafenib in patients with acute myeloid leukemia.
In this interview we discuss a bovine infectious agent, which may interact with carcinogens that arise during cooking or curing, and play a causative role in certain cancer.
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
According to three associated and recently published large randomized studies, while about 75% of cancer patients with major depression do not receive any treatment for their depression, a new system of integrating depression treatment into cancer patient care can transform patient outcomes.
In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.
In this preview of the 2014 San Antonio Breast Cancer Symposium, we take a look at some of the studies to watch for at this year's event.
Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.
